PHASE-II STUDY IN ADVANCED SARCOMA - RANDOMIZED TRIAL OF PYRAZOFURIN VERSUS COMBINATION CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CIS-DICHLORODIAMMINEPLATINUM(II) (CAP)
- 1 January 1980
- journal article
- research article
- Vol. 64 (4-5) , 655-658
Abstract
Patients (28) with various histologic types of measurable metastatic sarcoma were randomly assigned to receive treatment with combination cyclophosphamide, doxorubicin (adriamycin) and cis-dichlorodiammineplatinum(II) (CAP) or the single-agent, pyrazofurin. Patients who failed 1 arm of the protocol were eligible for cross-over treatment. Six of 24 patients treated with CAP achieved objective tumor regressions (25%) with a median duration of 11 mo. None of 21 patients receiving pyrazofurin achieved a response. CAP is an effective, well-tolerated combination for the treatment of advanced sarcoma.This publication has 3 references indexed in Scilit:
- Cis-diamminedichloroplatinum (II)Annals of Internal Medicine, 1977
- CHEMOTHERAPY OF ADVANCED L1210 LEUKEMIA WITH PLATINUM COMPOUNDS IN COMBINATION WITH OTHER ANTITUMOR AGENTS1977
- COMPARATIVE CLINICAL-TRIAL EVALUATING COMBINATION OF ADRIAMYCIN, DTIC, AND VINCRISTINE, COMBINATION OF ACTINOMYCIN-D, CYCLOPHOSPHAMIDE, AND VINCRISTINE, AND A SINGLE AGENT, METHYL-CCNU, IN ADVANCED SARCOMAS1976